Genomelink

Healthcare & Medical • United Statesgenomelink.io

Review data last updated August 10, 2026.

Request Custom AnalysisSign up free to see everything

Based on public reviews and response behavior.

Overall Score

42/100

−28.3 vs. last month3.75 ★ average rating · 600 reviews

Competitive Performance Rank

Among fully-analyzed Healthcare & Medical companies

#558of 615

Top 91% · Bottom Tier

#1 (best)#615 (worst)

#556Peer

#557Peer

#558This company

#559Peer

#560Peer

Overall Customer Sentiment

Below Average

61% of reviews positive, 38% negative

61%

positive

Positive61%
Neutral1%
Negative38%

Sentiment Balance

Covering September 2024 — 4 reviews, not the company's full review history.

Positive sentiment

Neutral sentiment

Negative sentiment

—

positive

Positive—
Neutral—
Negative—

Takeaway: Positive sentiment accounts for 25% of reviews in this period, with 75% negative and 0% neutral.

Sentiment Trend Over Time

Reviews (Count)

Showing 598 reviews across the months with enough data to chart reliably (min 3/month), most recent: September 2024.

Sentiment has been declining over the period shown.

Theme Distribution

Share of theme mentions

Customer Support

21.2%

Pricing

18.4%

Loyalty

13.4%

Product Quality

12.3%

Onboarding

10.0%

Most feedback concerns Customer Support.

The most common complaint theme is Pricing, making up 18.4% of all theme mentions.

Churn Signal Score

Rule-based: negative-review share, churn-intent phrases, and sentiment movement over time.

HIGH64/100

64/100

signal score

•Built from a negative-review share of 38.7% across this company's analyzed reviews.
•5 reviews contain phrases that signal intent to leave, such as cancelling or switching provider.
•Recent reviews are more negative than earlier ones, which pushes the signal up.

Reviewer Breakdown

Star split and recent-versus-earlier sentiment.

3.8avg rating

5★

50.8%

4★

13.2%

3★

13.5%

2★

5.7%

1★

16.8%

Based on 600 analyzed reviews. Sentiment is slipping: 61.9% of reviews in the last three months were positive, compared with 71.4% in the three months before that.

Unlock full insights